[{"id":"627558e9-c3d7-4f51-90e5-5a44fbbddb52","acronym":"","url":"https://clinicaltrials.gov/study/NCT01351103","created_at":"2021-01-18T05:31:16.537Z","updated_at":"2024-07-02T16:34:59.934Z","phase":"Phase 1","brief_title":"A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands","source_id_and_acronym":"NCT01351103","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF • RNF43","pipe":" | ","alterations":" BRAF mutation • RNF43 mutation","tags":["BRAF • RNF43"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • WNT974"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 185","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 06/14/2021","primary_completion_date":" 06/14/2021","study_txt":" Completion: 06/18/2024","study_completion_date":" 06/18/2024","last_update_posted":"2024-05-30"},{"id":"db9772f8-853e-4276-a288-f8213fb1a0f0","acronym":"PORCUPINE","url":"https://clinicaltrials.gov/study/NCT04907539","created_at":"2021-05-28T13:52:49.332Z","updated_at":"2024-07-02T16:35:06.261Z","phase":"Phase 2","brief_title":"A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)","source_id_and_acronym":"NCT04907539 - PORCUPINE","lead_sponsor":"Redx Pharma Plc","biomarkers":" RNF43 • RSPO2","pipe":"","alterations":" ","tags":["RNF43 • RSPO2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Prolia (denosumab) • zamaporvint (RXC004)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 04/02/2024","primary_completion_date":" 04/02/2024","study_txt":" Completion: 04/02/2024","study_completion_date":" 04/02/2024","last_update_posted":"2024-05-03"},{"id":"f206d692-a2fb-4635-9598-ebcf6ea572de","acronym":"KEYNOTE-E86","url":"https://clinicaltrials.gov/study/NCT04907851","created_at":"2021-06-01T18:53:39.917Z","updated_at":"2025-02-25T16:16:17.834Z","phase":"Phase 2","brief_title":"A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)","source_id_and_acronym":"NCT04907851 - KEYNOTE-E86","lead_sponsor":"Redx Pharma Plc","biomarkers":" RNF43","pipe":" | ","alterations":" RNF43 mutation","tags":["RNF43"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Prolia (denosumab) • zamaporvint (RXC004)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 12/10/2021","start_date":" 12/10/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2024-03-08"},{"id":"03e7603a-1cd4-4afe-8a3c-0dc20e27234c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02521844","created_at":"2021-01-18T12:11:30.833Z","updated_at":"2024-07-02T16:35:30.025Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours","source_id_and_acronym":"NCT02521844","lead_sponsor":"EDDC (Experimental Drug Development Centre), A*STAR Research Entities","biomarkers":" RSPO2 • RSPO3","pipe":" | ","alterations":" RSPO3 fusion","tags":["RSPO2 • RSPO3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RSPO3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ETC-159"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-11-08"},{"id":"8e871962-d882-425c-bf52-00aaa004787b","acronym":"Keynote 596","url":"https://clinicaltrials.gov/study/NCT02675946","created_at":"2022-01-26T19:54:54.091Z","updated_at":"2025-02-25T16:04:17.687Z","phase":"Phase 1b","brief_title":"CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)","source_id_and_acronym":"NCT02675946 - Keynote 596","lead_sponsor":"Curegenix Inc.","biomarkers":" BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • CGX1321"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2022-01-26"},{"id":"0f58a0ca-0ebd-407c-a07e-347f60642792","acronym":"","url":"https://clinicaltrials.gov/study/NCT02278133","created_at":"2021-01-18T10:43:25.747Z","updated_at":"2024-07-02T16:37:17.241Z","phase":"Phase 1/2","brief_title":"Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations","source_id_and_acronym":"NCT02278133","lead_sponsor":"Array BioPharma","biomarkers":" KRAS • RNF43","pipe":" | ","alterations":" KRAS mutation • BRAF V600 • KRAS wild-type • RAS wild-type • RNF43 mutation","tags":["KRAS • RNF43"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF V600 • KRAS wild-type • RAS wild-type • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • WNT974"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 05/31/2016","primary_completion_date":" 05/31/2016","study_txt":" Completion: 06/23/2017","study_completion_date":" 06/23/2017","last_update_posted":"2017-10-09"}]